Navigation Links
The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System

ZURICH, Switzerland, November 4, 2011 /PRNewswire/ --

Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.

Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ALFApump System were performed at Vienna General Hospital in October, under the supervision of Univ. Prof. Dr. Markus Peck-Radosavljevic, Vice-Chairman, Division of Gastroenterology and Hepatology (Chairman: Prof. Dr. M. Trauner), Dept. of Internal Medicine III. Vienna General Hospital is one of Europe's largest teaching hospitals. The ALFApump System is indicated for the management of refractory and recurrent ascites due to liver cirrhosis, a condition where massive and uncontrolled fluid accumulation occurs in the abdominal cavity.

"I believe that the ALFApump System represents a real breakthrough in the treatment of refractory ascites. By using the ALFApump, the patient no longer has to return to the hospital on a frequent basis to undergo drainage procedures. This positively impacts on both Quality of Life of the patient and the financial burden to the healthcare system.  The implant procedure for both patients went smoothly and without complications", commented Professor Peck-Radosavljevic.

Refractory ascites occurs when patients with ascites no longer respond to medical therapy. This condition affects over 100,000 patients in Europe and the US every year. The number of patients suffering from ascites is growing at approximately 10% a year due to the accelerating incidence of hepatitis- and obesity-related liver disease. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5-10 litres of ascites that has accumulated over a period of a week or two. The cumulative cost of ascites-related care for these patients often exceeds €40,000 each year.

The ALFApump System consists of a subcutaneously implanted battery-powered pump with a catheter placed in the abdominal cavity and another catheter connected to the bladder. The ALFApump System automatically and continually collects fluid as it forms in the abdominal cavity and moves it to the bladder, where it is eliminated through normal urination. The ALFApump is recharged wirelessly and can be programmed to meet the unique needs of each patient.

"We are delighted to be partnering with Professor Peck-Radosavljevic, the Medical University of Vienna and the Vienna General Hospital team", stated Dan Rose, Vice President of Commercial Operations.  "The ALFApump System is designed to offer patients better clinical outcomes and quality of life while eliminating the requirement for repeated expensive and burdensome invasive procedures."

About Sequana Medical:

Sequana Medical is a Swiss medical device company dedicated to improving patient lives through innovative technologies to manage fluid within the body.

Sequana Medical
Emily Woodward
Product Marketing Manager
Tel: +41-44-446-50-74

SOURCE Sequana Medical AG
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board
2. Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care
3. Access Medical Laboratories, Inc. to Celebrate Grand Opening of New Laboratory Headquarters in Jupiter, Florida
4. Modern Plastics Announces ISO 13485:2003 Certification for Medical Industry
5. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
6. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
7. TVM Capital MENA Marks Inauguration of ProVita International Medical Center
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. AWAC Becomes inVentiv Medical Management™
10. Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody
11. Offers Effective Ways to Combat Healthcare Fraud and Abuse in California, Florida, and Michigan
Post Your Comments:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):